Information on the total number of voting rights

Negma The group converted 180 convertible bonds resulting in a EUR 450,000 capital increase and Kreos/Pontifax vsconvertible bwaves have been reimbursed an amount of 3 million euros

Leuven, BELGIUMBoston, MA, USA – June 30 2022 8.00 PM CET – In accordance with article 15 of the Belgian law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and with miscellaneous provisions, Oxurion AG (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the information below regarding the conversion of Negma bonds, following the issuance of 1,216,216 new ordinary shares on June 7 (as listed on June 9) 2022, for a total amount of EUR 450,000, following the conversion of 180 convertible bonds under the Capital Commitment entered into with Negma Group.

Following the completion of the capital increase by conversion of the Negma convertible bonds, the total number of shares issued by Oxurion amounts to 49,821,189 ordinary shares in circulation with voting rights (compared to 48,604,973 ordinary shares in circulation previously). This number will serve as the denominator for the calculation of the participation percentages.

In addition, Oxurion repaid €3 million (30%) of the Kreos/Pontifax Convertible Bonds issued in December 2021. In this context, the cash covenant was reduced from €4 million to €3 million and the interest-only period has been extended until the end of the third quarter of 2022. The redemption reduces the total number of shares to be issued upon a possible conversion of the Kreos/Pontifax Convertible Bonds by 1,034,482 shares with no impact on the cash trail included in the Company’s Prospectus published in March 2022.

Therefore, Oxurion publishes the following updated information:

69,456,161.32
  • Total number of voting securities (all common shares)
49,821,189
  • Total number of ordinary shares (= denominator)
49,821,189
  • Number of outstanding subscription rights to securities with voting rights not yet issued:
  • 751,500 subscription rights (“PD”) issued on November 20, 2017, entitling their holders to subscribe for a total number of 751,500 securities carrying voting rights (all ordinary shares);
  • 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
  • 1,010,000 SRs issued on April 14, 2021, entitling their holders to subscribe for a total number of 1,010,000 voting securities (all ordinary shares);
  • 550,000 SRs issued on September 22, 2021, entitling their holders to subscribe for a total number of 550,000 securities with voting rights (all ordinary shares);
  • 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) LP and Pontifax Medison Finance (Cayman) LP) to subscribe to a total number of securities carrying vote (all ordinary shares) in accordance with the terms and conditions of such convertible bonds as attached to the agreement for the provision of a loan facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) LP and Pontifax Medison Finance (Cayman) LP, on November 21, 2021 and as amended following the partial redemption in June 2022;
  • 724,749 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 724,749 securities carrying voting rights (all ordinary shares); and
  • 220 convertible bonds issued on April 29, 2022, entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) according to the terms provided for in the issue and subscription agreement entered into between the Company and Negma Group on August 26, 2021.

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next-generation ophthalmic therapies designed to improve and better preserve vision in patients with retinal disorders, including diabetic macular edema (DME), the leading cause of vision loss. vision at work. -elderly, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic product for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for up to 50% of DME patients with a suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements contained in this press release may be considered “forward-looking”. These forward-looking statements are based on current expectations and, therefore, involve and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and assumes no obligation to update or revise any forward-looking statement, whether Consequently new information, future events or any other reason. Additional information regarding risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statements can be found in the company’s annual report. This press release does not constitute an offer or an invitation to sell or buy any securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption therefrom, and pursuant to all applicable U.S. securities laws. securities..

For more information, please contact:

  • OXUR PR_Voting rights (EN)_20220630

Comments are closed.